Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study

Secukinumab, a fully human monoclonal antibody, neutralizes interleukin-17A, a cornerstone cytokine driving the multiple manifestations of psoriasis. This post-hoc analysis of the SUPREME study was performed to determine the sustainability of response to secukinumab in terms of Psoriasis Area and Se...

Descripción completa

Detalles Bibliográficos
Autores principales: COSTANZO, Antonio, RUSSO, Filomena, GALLUZZO, Marco, STINGENI, Luca, SCUDERI, Roberta, ZICHICHI, Leonardo, PAPINI, Manuela, DI COSTANZO, Luisa, CONTI, Andrea, BURLANDO, Martina, CHIRICOZZI, Andrea, GAIANI, Francesca Maria, MUGHEDDU, Cristina, MUSUMECI, Maria Letizia, GISONDI, Paolo, PIASERICO, Stefano, DAPAVO, Paolo, VENTURINI, Marina, PAGNANELLI, Gianluca, AMERIO, Paolo, POTENZA, Concetta, PERIS, Ketty, CANTORESI, Franca, TREVISINI, Sara, LOCONSOLE, Francesco, OFFIDANI, Annamaria, MERCURI, Santo Raffaele, LORA, Viviana, PRIGNANO, Francesca, BARTEZAGHI, Marta, OLIVA, Giovanni, ALOISI, Elisabetta, ORSENIGO, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society for Publication of Acta Dermato-Venereologica 2021
Materias:
Clinical Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425609/
https://www.ncbi.nlm.nih.gov/pubmed/33903916
http://dx.doi.org/10.2340/00015555-3816

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425609/
https://www.ncbi.nlm.nih.gov/pubmed/33903916
http://dx.doi.org/10.2340/00015555-3816

Ejemplares similares